News
Videos
Conferences
Events
Resources
Subscribe

|Videos|December 1, 2020

ALK+ Metastatic Non-Small Cell Lung Cancer: The Importance of Biomarker Testing

Author(s)Jonathan W. Riess, MD, MS, UC Davis Comprehensive Cancer Center

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered unattainable.

Immune-Based Combinations Are Reshaping Liver Cancer Treatment

ByDr. Augusto Villanueva Rodriguez

November 20th 2025

Nona Baker received a diagnosis of essential thrombocythemia in 1991, followed by polycythemia vera in 2004.

Looking Back on a Blood Cancer Diagnosis Nearly 35 Years Later

November 20th 2025

Dr. Anne Chiang explains how biomarker testing and molecular profiling personalize lung cancer treatment and compare tissue versus liquid biopsies: © stock.adobe.com.

Your Genes, Your Treatment: Biomarker Testing and Lung Cancer

November 20th 2025

FDA sign image

FDA Accepts NDA for Zidesamtinib in Previously Treated ROS1+ NSCLC

November 20th 2025

"FDA" text.

FDA Approves Hyrnuo in Some with Locally Advanced/Metastatic NSCLC

November 19th 2025

Trending on CURE

Your Genes, Your Treatment: Biomarker Testing and Lung Cancer

Looking Back on a Blood Cancer Diagnosis Nearly 35 Years Later

Immune-Based Combinations Are Reshaping Liver Cancer Treatment

FDA Grants Fast Track Status to New Gastric Cancer Treatment

Understanding the Role of Nutrition in Kidney Cancer Care

© 2025 MJH Life Sciences^®

All rights reserved.